Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 5/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227586 | 0.76 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL22487790 | 0.75 | ADORA1 (0.38) | ADORA3ADORA1ADORA2ADDAH1 | |
| SCHEMBL9178197 | 0.75 | HRH4 (0.38) | ADORA3ADORA1ADORA2ADDAH1 | |
| SCHEMBL6290064 | 0.75 | PDCD1 (0.47) | PDCD1CD274HTR2CHTR2BHTR2A | |
| SCHEMBL5228377 | 0.73 | HTR2C (0.49) | ADORA3HTR2CHTR2B | |
| SCHEMBL18238079 | 0.70 | PDCD1 (0.40) | PDCD1CD274HTR2CHTR2BHTR2A | |
| SCHEMBL21672237 | 0.70 | PDCD1 (0.40) | PDCD1CD274HTR2CHTR2BHTR2A | |
| SCHEMBL19033524 | 0.70 | HTR2C (0.30) | HTR2C | |
| SCHEMBL12989184 | 0.69 | HRH4 (0.38) | ADORA3ADORA1ADORA2AHTR2CDDAH1 | |
| SCHEMBL18238710 | 0.67 | ADORA3 (0.32) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | PDCD1 365/4885CD274 584/4885ADORA3 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.